GOLDEN-505, a phase IIb study aimed at evaluating the efficacy and safety of Elafibranor, a dual PPARα/δ agonist, in patients with NASH, highlighted the lower NAFLD activity score, resolution of NASH without fibrosis, reduction in inflammatory markers, improvement in insulin sensitivity, glucose homeostasis and lipid metabolism [128]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.